| |
[摘要]：Hyponatremia is the most common electrolyte abnormality and has been associated with various morbidities, longer hospital stay and increased mortality. Until recently, options for treating hyponatremia were limited; however, the introduction of vasopressin antagonists has signaled the beginning of a new era in its treatment by addressing the responsible mechanism in the majority of cases: inappropriately high levels of vasopressin. By promoting aquaresis, or electrolyte-free water excretion, vasopressin antagonists could potentially play an important role in the treatment of euvolemic hyponatremia, typically encountered in the syndrome of inappropriate antidiuretic hormone secretion, and hypervolemic hyponatremia, seen in heart failure and cirrhosis. This review discusses lixivaptan, a selective, orally active, vasopressin V(2) receptor antagonist, and its potential use in the treatment of hyponatremia. |
|
